LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology Holdings Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, anno

Related Keywords

Netherlands , Irvine , California , United States , Amsterdam , Noord Holland , Johns Kovach , Flaurie Berman , Agendia Inc , Pondelwilkinson Inc , Business Development , Biotechnology Holdings Inc , Securities Exchange , Company Nasdaq , Lixte Biotechnology Holdings Inc , Exchange Commission , Lixte Biotechnology Holdings , Veteran Bas , Baan Brings Precision Oncology Expertise , Chief Executive Officer , Vice Chairman , Chief Scientific , Chief Clinical , Business Development Officer , Executive Chairman , United States Securities , Securities Act , Securities Exchange Act , Nc , The Company , Clinical Development , Clinical Stage , Cancer Therapy , Company , Bas Van Der Baan ,